Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2023-01-18 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
独立董事关于第三届董事会第十五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various matters discussed at the 15th meeting of the third board of directors of Shenzhen BGI Genomics Co., Ltd. It covers independent opinions on related party transactions, cash management, foreign exchange hedging, and liquidation of an associate company. The content focuses on governance and compliance with regulatory rules, board meeting decisions, and related party transactions. It does not contain financial statements or detailed financial results, nor is it a transcript or announcement of voting results. The document is a formal board/management related opinion, fitting best under Board/Management Information (MANG). The document length is short (1917 characters), and it is not an announcement of a report publication or a certification letter, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2023-01-18 Chinese
关于控股股东部分股份解除质押及再质押的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Shenzhen BGI Genomics Co., Ltd. regarding the partial release and re-pledging of shares by its controlling shareholder. It details the number of shares involved, pledge dates, pledgees, and the impact on shareholding percentages. The content focuses on share pledge and re-pledge activities, which relate to changes in share capital structure but do not involve new share issuance or buybacks. The document is relatively short (2186 characters) and is a specific announcement about share pledge status rather than a full financial report or earnings release. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as share pledges.
2023-01-18 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司2022年持续督导定期现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "定期现场检查报告" (Periodic On-site Inspection Report) by the sponsor (中信证券股份有限公司) for the company 深圳华大基因股份有限公司 for the year 2022. It contains detailed findings on corporate governance, internal controls, information disclosure, related party transactions, use of raised funds, and performance. The content is a detailed regulatory inspection report rather than a full annual or interim financial report. It is not an announcement or a brief summary but a substantive report on compliance and governance matters. This fits the category of an Audit Report / Information (AR), which includes standalone audit or inspection reports and results of regulatory checks. The document length (4723 characters) and detailed content support this classification with high confidence. FY 2022
2023-01-15 Chinese
关于第一期员工持股计划股票出售完毕的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of the sale of all shares held under the company's first employee stock ownership plan. It details the background, timeline, and compliance with regulations related to the employee stock plan, including the stock sale completion and future asset liquidation plans. There are no financial statements, earnings data, or detailed financial analysis present. The document is a formal disclosure of a corporate action related to employee stock plans, specifically the sale of shares held by employees. This fits best under the category of Regulatory Filings (RNS), as it is a regulatory announcement about a corporate event that does not fall under other specific categories like capital changes or management changes.
2023-01-12 Chinese
关于向武汉华大吉诺因生物科技有限公司增资暨关联交易的进展公告
Capital/Financing Update Classification · 95% confidence The document is a progress announcement regarding a capital increase (增资) and related party transaction involving Shenzhen BGI Genomics Co., Ltd. and Wuhan BGI Genomics Biotechnology Co., Ltd. It details the changes in registered capital and shareholding structure after the capital injection. The document is relatively short (2655 characters) and focuses on the update of a financing transaction rather than presenting financial statements or comprehensive financial data. It is not an annual or interim report, nor an earnings release or audit report. The content fits best under Capital/Financing Update (CAP) as it provides an update on the company's financing activity and capital structure changes related to an investment in an associate company.
2022-12-30 Chinese
关于控股股东部分股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge of shares by the controlling shareholder of Shenzhen BGI Genomics Co., Ltd. It details the number of shares pledged, the proportion of shares pledged relative to total holdings and company capital, and other related information. The document is short (1834 characters) and focuses on a specific capital-related event (share pledge). It does not contain financial statements, management discussion, or audit information. It is not a report but an announcement about a change in shareholding status related to share pledges. This fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as share pledges.
2022-12-26 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.